JP Morgan maintains Celanese at Overweight, raises price target to $77 from $76

JP Morgan reaffirmed its Overweight rating for Celanese and increased its price target to $77 from $76, suggesting a 52.9% upside from the Nov 3 close of $50.36, according to the firm.

Original reporting
Published Nov 4, 2026, 7:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 7:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JP Morgan maintains Celanese at Overweight, raises price target to $77 from $76 — source image
Decision brief

The 30-second read

$CEBullishLow
01

Why it matters

For traders, the actionable element is the sentiment shift from the raised target, but the lack of new operating or financial disclosures limits decision-making value.

02

Market read

Valuation sentiment for CE improves slightly due to the higher target, but the article does not introduce new fundamentals.

03

What to watch

Without any new earnings, guidance, or demand/supply update, traders may focus more on upcoming company catalysts than on the revised target.

Relevance 4/10Novelty 3/10Timing: as-of the analyst note publication date, for near-term sentiment

Background

The piece is an analyst action summary: JPMorgan reiterates an Overweight rating and nudges the price target upward by $1.

Company-level read

Ticker impact

$CEBullishMedium confidence
Context

JPMorgan maintained Celanese at Overweight and raised its price target to $77 from $76, signaling a modest valuation uplift.

Expected impact

Likely limited upside bias as traders price in the higher target, with follow-through depending on broader market sentiment toward chemicals.

Evidence & confidence

The only disclosed catalyst is an analyst target change (no earnings, guidance, or operational update), which typically drives smaller, shorter-lived moves unless accompanied by new fundamental information.

Market effects

A positive CE target can marginally support sentiment for specialty chemicals, but the article is single-name and lacks sector-wide data.

No direct regional market linkage is provided.

No global macro or cross-border catalyst is mentioned.

Counterpoint

The target increase may be incremental and not reflect new information, so the market may already discount it or treat it as routine analyst maintenance.

Key entities

  • Celanese

    Specialty chemicals company covered by JPMorgan, with an Overweight rating and a raised $77 price target.

Related articles

$CEMed

BMO raises Celanese stock price target to $58 on cost cuts

BMO Capital increased its price target for Celanese (NYSE:CE) to $58 from $56, citing cost-cutting and cash generation. The firm expects higher estimates for 2027-2028 due to growth in engineered materials, despite challenges in the acetyl chain business. Celanese reported Q3 2026 earnings of $1.65 per share, beating estimates, but revenue fell short. Other analysts have also raised price targets.

$CEMed

Celanese Corp (CE) Q3 2026 Earnings Call Highlights: 2027 Free Cash Flow Outlook

Celanese Corp (CE) reported Q3 2026 earnings, with CFO Chuck Kyrish highlighting $70M in cost savings this year and $30M-$40M expected in 2027. CEO Scott Richardson noted strong demand from AI data center build-outs driving growth in electronics. Q4 guidance includes a 6-7% volume decline in Engineered Materials and a $25M decline in acetyls. The company expects margin compression in Q4 due to methanol prices and other cost pressures.

$CEMedAI 8/10

Celanese Q3 Earnings Call Highlights

Celanese (NYSE: CE) expects restructuring costs to decrease by $30M-$40M in 2027 and additional cost savings of $30M-$40M in 2027. The company targets $150M in productivity improvements to offset inflation. Engineered Materials segment sees growth in electronics and healthcare, while automotive and nylon conditions remain mixed. Acetyl Chain faces margin compression due to outages and cost pressures.

$CEMed

Celanese (CE) Q3 2026 Earnings Call Transcript

Celanese (CE) reported Q3 2026 earnings, highlighting $100M in cost savings for 2027 and $700M-$800M in free cash flow. The company expects growth in electronics and healthcare segments to continue into 2027, while addressing potential capacity needs in downstream derivatives. Management discussed market dynamics in Asia and the impact of tariff changes on VAM. According to the company, they remain focused on productivity and targeted investments.

$CEMedAI 8/10

Celanese Q3 2026 slides: specialty focus drives margin gains

Celanese (NYSE:CE) reported Q3 2026 earnings with revenue of $2.56B, missing estimates, but EPS of $1.65 beat expectations. The company highlighted strong free cash flow of $461M and raised full-year guidance to $750M-$800M. Shares rose 3.86% to $49.79. Celanese is shifting focus to high-margin specialty applications in medical and electronics, driving margin expansion.

$CEHighAI 8/10

Why is Celanese stock rallying today?

Celanese (CE) stock rose 4.3% in pre-market trading after reporting Q3 adjusted EPS of $1.65, beating estimates. Revenue grew 6% YoY to $2.56B, missing slightly. The company raised its full-year 2026 EPS guidance to $6.00–$6.25. Analysts Mizuho and BofA increased price targets. The S&P 500 and NASDAQ showed mild gains.